Hemgenix continues to be provided ‘conditional authorisation’. Consequently the European Medicines Agency determined that the advantages of Hemgenix are better than its dangers, but the company must provide supplemental evidence soon after authorisation.Gurus pointed out that the number of sufferers predicted to acquire etranacogene dezaparvove